Zydus Lifesciences has informed that it enclosed a copy of press release dated March 24, 2023 titled ‘Zydus receives final Approval from the USFDA for Doxepin Hydrochloride Capsules USP, 150 mg’.
The above information is a part of company’s filings submitted to BSE.